Particulate matter (PM) is one of six damaging air pollutants that has been identified under the Clean Air Act of 1970 and is regulated for the sake of protecting human health. The harmful effects of outdoor PM have been well established and include premature death ([@b32-ehp-117-294]) and worsening of asthma morbidity ([@b19-ehp-117-294]; [@b29-ehp-117-294]; [@b30-ehp-117-294]; [@b31-ehp-117-294]; [@b46-ehp-117-294]). The evidence of the effect of indoor PM on asthma health is not as well established. The indoor environment is especially important in the context of asthma because Americans spend most of their time indoors, and improvement of indoor air quality could therefore provide an important opportunity to better asthma health. Indoor PM differs from outdoor PM in concentration, source, and composition ([@b1-ehp-117-294]; [@b18-ehp-117-294]; [@b35-ehp-117-294]; [@b42-ehp-117-294]; [@b43-ehp-117-294]). Thus, we cannot simply extrapolate the health effects of indoor PM from studies of outdoor air.

Under the [@b10-ehp-117-294], the National Ambient Air Quality Standards (NAAQS) have defined limits for acceptable daily and annual concentrations of outdoor PM \< 2.5 μm and \< 10 μm in diameter (PM~2.5~ and PM~10~, respectively) \[[@b37-ehp-117-294]\]. More recently, there has been interest in developing standards for the coarse thoracic particles that are between 2.5 and 10 μm in diameter (PM~2.5--10~), which, unlike PM~10~, do not include the PM~2.5~ (fine PM) fraction. In the recent 2006 NAAQS update, PM~2.5~ standards were made more stringent based on substantial scientific evidence of detrimental health effects ([@b39-ehp-117-294]). There was a simultaneous proposal to replace the existing daily PM~10~ standards with a PM~2.5--10~ (coarse PM) standard in urban areas only ([@b39-ehp-117-294], [@b40-ehp-117-294]). However, in the final NAAQS, the annual PM~10~ standard was revoked and the daily PM~10~ standard was retained without replacement by a PM~2.5--10~ standard because of lack of sufficient evidence of adverse health effects. The U.S. EPA will continue to monitor PM~2.5--10~ in sites throughout the United States and has recognized the need for further research on the health effects of coarse PM.

The [@b28-ehp-117-294] has outlined as a top research priority the identification of subpopulations at risk of adverse health outcomes related to PM exposure. Inner-city African-American children incur a disproportionate burden of asthma morbidity compared with other U.S. children ([@b2-ehp-117-294]; [@b23-ehp-117-294]). Although there are many hypothesized contributors to the disparities in asthma morbidity in the United States, including access to medical care, exposure to child care settings or other children, diet, and stress, exposure to environmental pollutants may play an important role ([@b15-ehp-117-294]). Inner-city African-American children with asthma may be a susceptible subpopulation because they are more likely to live in geographic areas with poor outdoor air quality ([@b2-ehp-117-294]), and ongoing exposure to home indoor air of suboptimal quality may confer additional risk to asthma health. The goal of the present study was to investigate the effect of in-home coarse and fine PM on respiratory symptoms, rescue medication use, and acute health care use among preschool asthmatic children living in inner-city Baltimore. We selected a population of inner-city, predominantly minority children as a potentially susceptible subpopulation.

Materials and Methods
=====================

Study design
------------

The Baltimore Indoor Environmental Study of Asthma in Kids is a longitudinal study that was designed to investigate the role of indoor pollutants and allergens on asthma ([@b12-ehp-117-294]; [@b20-ehp-117-294]). We evaluated participating children at baseline and at 3 and 6 months. At each time interval, environmental monitoring occurred for 3 consecutive days, and we assessed health outcomes through caregiver report. The Johns Hopkins Medical Institutional Review Board approved the study, and all participants provided informed consent before beginning the study.

Participants
------------

Recruitment for this study began in September 2001, and we completed the last follow-up visit in April 2004. We recruited participants from the health systems that provide care to most residents of East Baltimore, Maryland. To ascertain the diagnosis of asthma, we used a two-stage process. We identified children as potentially eligible if they had a health care encounter for asthma with an ICD-9 \[*International Classification of Diseases, 9th Revision* ([@b45-ehp-117-294])\] code of 493.X in the previous 12 months. To confirm the diagnosis, participants had to report a physician diagnosis of asthma and had to have symptoms of asthma and/or medication use for asthma in the previous 6 months. Other inclusion criteria were age between 2 and 6 years and residence within one of nine contiguous ZIP codes within East Baltimore. Based on 2000 U.S. Census data, the ZIP codes of homes included in the study represented a geographic region that is \> 99% urban ([@b36-ehp-117-294]).

Air quality assessment
----------------------

A trained environmental technician completed home visits. We conducted environmental monitoring at baseline and at 3 and 6 months. At each time period, we performed integrated air sampling in the child's bedroom over a 3-day period. We chose the child's bedroom as the indoor monitoring site because the bedroom represents an environment where we expected the child to spend a substantial portion of time while indoors. We conducted air sampling continuously over 72 hr using PM~10~ and PM~2.5~ 4 L/min MSP impactors (St. Paul, MN) loaded with 37-mm, 2.0-μm pore-size, Teflo polytetrafluoroethylene membrane filters with polypropylene support rings (Pall Corporation, Ann Arbor, MI). We calculated coarse PM fraction as the difference between PM~10~ and PM~2.5~, a method that has been commonly used to assess coarse PM concentrations ([@b8-ehp-117-294]; [@b41-ehp-117-294]). Inlet flow rates were calibrated at the beginning and end of each sampling period using primary standards (DryCal; Bios International Corporation, Butler, NJ). PM gravimetric analysis was conducted on a Mettler T5 microbalance (Mettler Toledo, Inc., Columbus, OH), after filters were pre-equilibrated for 24 hr at constant temperature and humidity. We measured in-home temperature and humidity concurrently using a HOBO temperature and humidity data logger (Onset Corporation, Pocasset, MA). We measured ambient PM for the study at a central site located within the study area using standard methods ([@b37-ehp-117-294]). All homes were within 2 miles of the central monitoring site. PM~2.5~ was collected using the PM~2.5~ Partisol-Plus model 2025 FRM sequential air sampler (Rupprecht & Patashnick Co. Inc., Albany, NY) and PM~10~ using a tapered element oscillating microbalance (TEOM 1400; Rupprecht & Patashnick). For this analysis, when ambient values were missing from the central site, values were supplemented from the Maryland Department of the Environment Old Town Station, a reporting site for the U.S. EPA ambient air monitoring network that is within 1 mile of the central monitoring site ([@b38-ehp-117-294]).

Clinical evaluation
-------------------

We evaluated participants at baseline and at 3 and 6 months. During the baseline clinic visit, each child underwent skin prick testing (Multi-Test II; Lincoln Diagnostics, Decatur, IL) to 14 aero-allergens: American and German cockroach, dust mite mix, cat dander, dog hair/dander, mouse epithelia, rat epithelia, three pollens (Eastern Oak mix, grass mix, ragweed mix), and four molds (*Helminthosporium*, *Alternaria*, *Penicillium*, and *Aspergillus*). Atopy was defined as at least one positive skin test result to the panel of allergens tested.

Once during each of the three monitoring periods, caregivers completed a health questionnaire that included closed-ended questions from the International Study of Asthma and Allergies in Childhood ([@b3-ehp-117-294]) and the Children's Health Survey for Asthma ([@b4-ehp-117-294]) to evaluate indicators of asthma health. Questions ascertained information about acute health care use in the prior 3 months (emergency department visits, unscheduled doctor visits, and hospitalizations) and days of rescue medication use in the previous 2 weeks (short-acting beta agonist). We also asked caregivers about the child's symptoms in the previous 2 weeks, including *a*) wheezing, coughing, or tightness in the chest; *b*) the need to slow down or stop activities because of asthma symptoms; *c*) wheezing so badly that the child could only speak one or two words at a time between breaths; *d*) symptoms with exercise; and *e*) nocturnal symptoms. We quantified each symptom as the number of days that the symptom was present in the previous 2 weeks (0--14 days).

Caregivers also completed a daily activity diary that detailed activities that occurred in the home during three time periods, morning (6000--1200 hours), afternoon (1200--1800 hours), and evening (1800--0600 hours). They recorded the number of windows that were open for \> 10 min during each of these time periods. Caregivers also recorded the time that the child spent in the home, including the room where the environmental monitors were placed, in the daily diary.

Statistical analysis
--------------------

We generated summary statistics using means or proportions, as appropriate. We made comparisons using the chi-square test for proportions and Student's *t*-test for continuous data. We used negative binomial regression models with generalized estimating equations (GEE) ([@b47-ehp-117-294]) to model the relationship between 3-day average PM and three repeated measures of days of symptoms or rescue medication use during the previous 2 weeks. We used logistic regression models with GEE to model the relationship between PM concentration and odds of an acute health care encounter (hospitalization, emergency department visit, and unscheduled doctor visit). We constructed multivariate models to account for potential confounders that we identified based on a known relationship with asthma or with PM, or based on a statistically significant association with either, in bivariate analyses. These covariates included age, sex, race, parent education level, season, and ambient PM. The number of open windows in the home was not included in the final multivariate models because the addition of this variable had no substantial effect on the results. We performed all analyses with StataSE statistical software (version 8.0; StataCorp, College Station, TX). Statistical significance was defined as *p* \< 0.05.

Results
=======

The 150 children were between 2 and 6 years of age and were predominantly African American (91%) and from households of low socioeconomic status ([Table 1](#t1-ehp-117-294){ref-type="table"}). More than two-thirds of the children were atopic. The children had evidence of active asthma symptoms ([Table 2](#t2-ehp-117-294){ref-type="table"}), and 62% met classification criteria for persistent asthma ([@b25-ehp-117-294], [@b26-ehp-117-294]). Children spent, on average, 14 of every 24 hr in their homes, and approximately half of this time they spent in the room where the environmental monitoring occurred.

Characteristics of the PM measured indoors
------------------------------------------

The mean (± SD) concentration for indoor PM~2.5--10~ was 17.4 ± 21.1 μg/m^3^, and for PM~2.5~ was 40.3 ± 35.4 μg/m^3^. The mean indoor PM~2.5~ concentrations did not differ significantly by season (summer, 37.6 ± 31.6 μg/m^3^; fall, 40.2 ± 33.3 μg/m^3^; winter, 40.2 ± 39.7 μg/m^3^; spring, 42.7 ± 36.6 μg/m^3^; *p* = 0.65). The mean indoor PM~2.5--10~ concentrations were significantly lower in the summer (12.83 ± 14.90 μg/m^3^) compared with the other seasons (fall, 18.14 ± 18.22 μg/m^3^; winter, 16.16 ± 12.19 μg/m^3^; spring, 20.85 ± 30.91 μg/m^3^; *p* \< 0.01). The in-home PM~2.5--10~ and PM~2.5~ concentrations were significantly higher than the respective average ambient measurements made over the same time period (10.3 ± 21.0 μg/m^3^ and 12.4 ± 6.2; *p* \< 0.01 for both comparisons) ([Figure 1](#f1-ehp-117-294){ref-type="fig"}).

Effects of coarse PM on asthma health
-------------------------------------

Higher concentrations of coarse PM measured indoors were associated with substantial increases in asthma symptoms in both the bivariate and the multivariate models ([Tables 3](#t3-ehp-117-294){ref-type="table"}, [4](#t4-ehp-117-294){ref-type="table"}). For example, for every 10-ug/m^3^ increase in indoor PM~2.5--10~ concentration, there was a 6% \[95% confidence interval (CI), 1 to 12%; *p* = 0.02\] increase in the number of days of cough, wheeze, or chest tightness, after adjusting for age, race, sex, socioeconomic status, season, indoor fine PM, and ambient fine and coarse PM concentrations. In the adjusted models, higher indoor coarse PM concentration was also significantly associated with symptoms severe enough to slow a child's activity, with wheezing that limited speaking ability, and with nocturnal symptoms with an 8% (95% CI, 2 to 14%; *p* = 0.01), an 11% (95% CI, 3 to 19%; *p* \< 0.01), and an 8% (95% CI, 1 to 14; *p* = 0.02) increase in symptom days per 10-ug/m^3^ increase in PM~2.5--10~, respectively. For every 10-ug/m^3^ increase in PM~2.5--10~, there was a 6% (95% CI, 1 to 10%; *p* = 0.02) increase in days of rescue medication use, after adjusting for potential confounders. We found no significant associations between PM~2.5--10~ measured indoors and acute health care use, as measured by emergency department visits, unscheduled doctor visits, and hospitalizations (data not shown). Ambient PM~2.5--10~ was not significantly associated with respiratory symptoms, rescue medication use, or acute health care use in multivariate analyses adjusting for simultaneously measured indoor PM (data not shown).

Effects of fine PM on asthma health
-----------------------------------

Fine PM was also positively associated with respiratory symptoms and with rescue medication use ([Tables 3](#t3-ehp-117-294){ref-type="table"} and [4](#t4-ehp-117-294){ref-type="table"}). For example, for every 10-μg/m^3^ increase in PM~2.5~ measured indoors, there was a 7% (95% CI, 0 to 14%; *p* = 0.04) increase in days of wheezing severe enough to limit speech and a 4% (95% CI, 1 to 8%; *p* = 0.04) increase in days on which rescue medication was needed, after adjustment for potential confounders. We found no significant associations between in-home or ambient PM~2.5~ concentrations and acute health care use (data not shown).

Effects of PM on exercise-related symptoms
------------------------------------------

Both indoor and ambient fine PM concentrations were associated with exercise-related respiratory symptoms. In the bivariate models, for every 10-μg/m^3^ increase in indoor and ambient PM~2.5~, there was a 4% (95% CI, 1 to 7%; *p* = 0.04) and a 15% (95% CI, --4 to 35%; *p* = 0.13) increase in days of exercise-related symptoms, respectively. In the multivariate models adjusting for participant characteristics that were potential confounders as well as for simultaneous indoor and ambient coarse PM, for every 10-μg/m^3^ increase in indoor and ambient PM~2.5~, there was a 7% (95% CI, 2 to 11%; *p* \< 0.01) and a 26% (95% CI, 1 to 52%; *p* = 0.04) increase in days of exercise-related symptoms, respectively. In contrast, neither indoor nor ambient coarse PM concentrations were associated with exercise-related symptoms.

Discussion
==========

Among inner-city children, most of whom were African American, we found that PM concentrations measured indoors were significantly associated with asthma symptoms and rescue medication use. In our cohort, indoor fine and coarse PM concentrations were associated with increases in respiratory symptoms that were clinically significant in terms of their magnitude. For example, a 10-μg/m^3^ increase in PM~2.5--10~ concentration was associated with an 8% increased incidence in days of symptoms severe enough to slow a child's activity.

Our findings are consistent with what is known about the effects of indoor PM on childhood asthma and provide new evidence of a detrimental health effect of indoor coarse PM. In a previous study, [@b11-ehp-117-294] investigated PM exposures among 19 school-age children with asthma living in California and found that forced expiratory volume in 1 sec was inversely associated with personal, indoor, and ambient PM~2.5~ and PM~10~. They found stronger associations with indoor than with ambient PM concentrations among these children but did not evaluate the effects of PM on symptoms or medication use. Studies of school-age children in Seattle, Washington, have shown that indoor PM~2.5~ exposure was associated with decreased pulmonary function in a subgroup of 11 children not taking inhaled corticosteroids, but these studies did not include indoor measurements of PM~2.5--10~ ([@b17-ehp-117-294]; [@b34-ehp-117-294]). Thus, the present study, which includes a much larger sample size compared with previous studies, adds to the growing evidence that indoor PM exposure adversely affects asthma health and provides for the first time evidence that exposure to the indoor coarse (PM~2.5--10~) fraction is harmful for children with asthma, especially those of preschool age.

Our findings demonstrate that both indoor coarse and fine PM distinctly affect respiratory health. There are physiologic reasons that can explain why PM of these different size fractions can contribute separately to asthma morbidity. *In vitro* studies have shown that coarse PM preferentially induces inflammatory mediators in bronchial epithelial cells and alveolar macrophages compared with fine PM and that bacterial and endotoxin components of coarse PM may play a key role in this process ([@b6-ehp-117-294], [@b5-ehp-117-294]). Although fine PM may be capable of reaching the alveoli, regions responsible for gas exchange, the deposition of coarse PM in conducting airways and subsequent bronchial hyperreactivity may be driving the symptomatic response measured in these preschool children. Although analyzing the composition of the PM and investigating the mechanism by which PM exacerbates asthma are beyond the scope of the present investigation, fine and coarse PM are known to have different sources, compositions, and deposition patterns in the respiratory tract, all of which may contribute to the differential health effects reported in our study. Understanding the components of indoor PM and the mechanism by which PM exacerbates asthma will be an important focus of future studies.

The strong relationship between indoor and ambient fine PM exposure and exercise-related symptoms was striking. Previous investigators have suggested that exercise may play a role in asthma by modifying the effect of environmental stimuli and pollutants. In a study of asthmatic children, [@b21-ehp-117-294] found that nitrogen dioxide was associated with bronchitic symptoms only among children participating in team sports. The authors hypothesized that the increased minute ventilation may in part explain why the effect of NO~2~ was modified by exercise. Our findings of increased exercise symptoms in response to fine PM exposure may be attributable to increased minute ventilation and an increased dose of fine PM in the distal airways and the pulmonary circulation that is more potent in eliciting exercise-related symptoms than the doses of coarse PM that deposit in the more proximal airways.

The study population is a key strength of our study design. We were able to enroll a study population of predominantly African-American, inner-city children who spent a substantial portion of time in their homes. Our results may provide insight about a potentially important contributor to the high burden of asthma in this population. African Americans are more likely than whites to live in geographic regions with poor outdoor air quality. For example, in 2002, 71% of African Americans lived in counties that violated federal air pollution standards, compared with 58% of the white population ([@b2-ehp-117-294]). Suboptimal indoor environments may contribute additional risk beyond that of the poor outdoor air quality. In Baltimore, a previous study has demonstrated that among children with asthma, those living in the inner city had in-home PM concentrations that were two to three times greater than did those in the local suburbs ([@b33-ehp-117-294]). Compared with what is considered acceptable quality for outdoor air, the children in the present study lived in homes with relatively elevated PM concentrations. For example, 85% of children lived in homes that would fail to meet the NAAQS annual standard for acceptable ambient air quality and 55% lived in homes that would fail to meet the more stringent 24-hr standard ([@b37-ehp-117-294]). We have demonstrated that PM concentrations in the indoor air are associated with additional asthma morbidity after controlling for the effects of ambient PM measured simultaneously. Thus, indoor PM exposure may be an important contributor to the disproportionate burden of disease among African Americans living in inner cities.

Avoidance of harmful environmental exposures is a key component of national and international guideline recommendations for management of asthma ([@b14-ehp-117-294]; [@b27-ehp-117-294]). Guidelines identify PM as a pollutant of concern, but specific recommendations are limited and focus mostly on avoiding exposure to elevated outdoor concentrations. This approach may imply that the indoor environment confers an advantage of lower exposure. However, our results demonstrate that the indoor environment may be less favorable in some circumstances. Although some previous studies have found indoor PM concentrations that are similar to or lower than outdoor concentrations ([@b17-ehp-117-294]; [@b35-ehp-117-294]), our findings are consistent with previous studies that have demonstrated indoor PM concentrations that greatly exceed outdoor concentrations ([@b7-ehp-117-294]; [@b16-ehp-117-294]; [@b42-ehp-117-294]; [@b43-ehp-117-294]). Current recommendations for improving home indoor air quality focus mostly on avoidance of indoor environmental tobacco smoke. However, there are other important modifiable sources of indoor PM, including common cleaning and cooking activities ([@b22-ehp-117-294]; [@b43-ehp-117-294]). In urban environments especially, penetration of outdoor air, which contains traffic-related PM, into the indoors may also be an important contributor to the composition of the indoor air ([@b35-ehp-117-294]). In the present study, the homes were all in the inner city, and most were close to the road, making exposure to traffic-related urban dust a likely contributing factor to the composition of PM in most homes. Thus, our results are most generalizable to populations of children who live in urban settings. Although our study cannot determine which sources of indoor PM are responsible for exacerbating asthma symptoms, previous studies have shown that PM concentrations can be lowered indoors ([@b13-ehp-117-294]). Such studies have shown that a multifaceted indoor environmental control approach can reduce asthma morbidity, but the independent effect of PM reduction has not yet been determined ([@b13-ehp-117-294]; [@b24-ehp-117-294]). Intervention studies to assess the impact of improving indoor air quality on asthma symptoms and which PM reduction methods are most beneficial will be critical to provide data to inform guidelines and policy initiatives.

A limitation of this study is the potential for measurement error. Although the study area was relatively homogeneous, and all homes were within 2 miles of the central monitoring site, we took estimates of outdoor PM exposure from a central monitoring site rather than outdoor monitoring at the individual home. This approach could have resulted in nondifferential measurement error and may have contributed to the lack of a significant health effect of ambient PM exposure on non-exercise-related symptoms. The methods of sampling indoor, and ambient air differed and although we did not conduct side-by-side comparisons, systematic differences of up to 17% have been previously reported ([@b44-ehp-117-294]). We obtained the PM~2.5--10~ concentrations by subtracting PM ~2.5~ concentrations from PM~10~, making the PM~2.5--10~ measurement subject to greater error than either individual measurement. We determined that the precision of the indoor PM~2.5~ and PM~10~ measures, determined by collocated samplers, were ±7% and ±6%, respectively, resulting in an expected error in PM~2.5--10~ of 9%, which is consistent with the precision described previously ([@b9-ehp-117-294]; [@b41-ehp-117-294]; [@b44-ehp-117-294]). Importantly, we conducted environmental monitoring in the same manner for all study participants and did not differ it based on asthma status. Thus, nondifferential measurement error would be expected to bias our results toward the null and would not be responsible for the observed association between indoor PM concentrations and asthma symptoms in this study.

In the present longitudinal study, fine and coarse PM concentrations measured indoors were associated with increased asthma morbidity, including more frequent respiratory symptoms and rescue medication use, among inner-city minority children. Although the present study cannot delineate which sources of PM measured indoors were responsible for the observed health effects, these findings suggest that improving air quality in the indoor environment with a strategy that reduces PM concentration may improve asthma health. These findings do not negate the importance of optimizing outdoor air quality, because outdoor PM concentrations are linked to adverse health effects, especially among those with underlying pulmonary disease, and outdoor air is an important determinant of the composition of indoor air. Instead, improving indoor air quality and lowering indoor PM concentrations may provide an additional means of improving asthma health, especially among children living in inner cities.
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###### 

Participant characteristics (*n* = 150).

  Characteristic                   Value
  -------------------------------- ------------
  Age \[years; mean (range)\]      4.4 (2--6)
  Race (%)                         
   African American                91
   Caucasian                       5
   Other                           4
  Sex (% male)                     58
  Caregiver education level (%)    
   Eighth grade/some high school   38
   High school                     43
   Some college                    19
  Health insurance (%)             
   Public                          89
   Private                         9
   Self-pay                        2

###### 

Baseline asthma status.

  Characteristic                                                      Value
  ------------------------------------------------------------------- -------------
  Atopic (%)                                                          69
  Acute care use in the past 3 months (%)                             
   Emergency department visit                                         24
   Hospitalization                                                    3
   Unscheduled doctor visit                                           18
  Days of symptoms in the past 2 weeks (mean ± SD)                    
   Cough, wheezing, chest tightness                                   2.16 ± 3.37
   Slow down because of symptoms                                      1.92 ± 3.79
   Symptoms with running                                              1.60 ± 3.13
   Nocturnal symptoms                                                 1.69 ± 3.49
   Limited speech                                                     0.33 ± 1.20
  Days of rescue medication use in the previous 2 weeks (mean ± SD)   3.77 ± 5.19

###### 

Indoor PM concentrations, asthma symptoms, and rescue medication use: bivariate models.

                                     PM~2.5--10~ (per 10-μg/m^3^ increase)   PM~2.5~ (per 10-μg/m^3^ increase)                       
  ---------------------------------- --------------------------------------- ----------------------------------- ------------------- ------
  Cough, wheezing, chest tightness   1.05 (0.99--1.10)                       0.08                                1.01 (0.98--1.05)   0.41
  Slow down                          1.08 (1.03--1.13)                       \< 0.01                             1.00 (0.97--1.04)   0.85
  Symptoms with running              1.03 (0.97--1.09)                       0.39                                1.04 (1.01--1.07)   0.04
  Nocturnal symptoms                 1.06 (1.01--1.11)                       0.03                                1.02 (0.98--1.05)   0.37
  Limited speech                     1.11 (1.05--1.18)                       \< 0.01                             1.01 (0.95--1.07)   0.33
  Rescue medication use              1.06 (1.02--1.11)                       \< 0.01                             1.03 (1.00--1.6)    0.06

IRR, incidence rate ratio.

###### 

Indoor PM concentrations, asthma symptoms, and rescue medication use: multivariate models.

                                     PM~2.5--10~ (per 10 μg/m^3^ increase)[a](#tfn3-ehp-117-294){ref-type="table-fn"}   PM~2.5~ (per 10 μg/m^3^ increase)[b](#tfn4-ehp-117-294){ref-type="table-fn"}                       
  ---------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------- ---------
  Cough, wheezing, chest tightness   1.06 (1.01--1.12)                                                                  0.02                                                                           1.03 (0.99--1.07)   0.18
  Slow down                          1.08 (1.02--1.14)                                                                  0.01                                                                           1.04 (1.0--1.09)    0.06
  Symptoms with running              1.00 (0.94--1.08)                                                                  0.81                                                                           1.07 (1.02--1.11)   \< 0.01
  Nocturnal symptoms                 1.08 (1.01--1.14)                                                                  0.02                                                                           1.06 (1.01--1.10)   0.01
  Limited speech                     1.11 (1.03--1.19)                                                                  \< 0.01                                                                        1.07 (1.00--1.14)   0.04
  Rescue medication use              1.06 (1.01--1.10)                                                                  0.02                                                                           1.04 (1.01--1.08)   0.04

IRR, incidence rate ratio.

Adjusted for age, sex, race, parent education level, season, indoor fine PM, ambient fine PM, ambient coarse PM.

Adjusted for age, sex, race, parent education level, season, indoor coarse PM, ambient coarse PM, ambient fine PM.
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